Press Detail





Biotest receives go-ahead to export culture media to the USA

Biotest AG / Product Launch

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------

Biotest receives go-ahead to export culture media to the USA

· Affiliate heipha is granted certification for the export of  culture
media
· Focus on hygiene monitoring in the pharmaceutical industry
· Biotest Diagnostics Corporation launched sales this week

Dreieich/Eppelheim/Denville, 15 June 2007. The Biotest Group has taken a
key step forward in the expansion of its diagnostic business in the USA.
heipha Dr. Müller GmbH in Eppelheim, Germany, the majority of which is
owned by the Biotest Group, has been granted comprehensive licences from
the United States Department of Agriculture (USDA) to export culture media
to the USA: Certification was granted for fulfilment of the strict
regulatory requirements at the end of May following close inspection
carried out by the responsible veterinary authorities. The requirements
stipulate, for example, that the origin of all raw materials must be free
of any risk of potential contamination from the BSE agent. In order to
ensure this, heipha has developed a comprehensive quality assurance system
in recent months, which can be verified by the responsible authorities at
any time.

The USA represents the world's biggest market for microbiological
diagnostic products. The market volume for ready culture media in North
America alone totals $225 million with a growth rate of approximately 10%
per annum. There is a strong focus on the pharmaceutical industry, where
one of the uses of heipha's culture media is hygiene monitoring – for
example, for the control of bacteria in cleanrooms or insulators, in
sterility testing or the identification of microorganisms in clinical
research material. Sales will be carried out by Biotest Diagnostics
Corporation (BDC) in Denville/USA, where the sales team has already been
reinforced. The market launch took place in the form of an sales force
conference in New Orleans on 14 June. heipha has already started supplying
culture media to BDC.

Harro Walger, Managing Director of heipha commented: 'With particle
counters and air samplers, Biotest's microbiology is already well
positioned in the USA. The heipha product range complements the existing
offering, which again provides for a marked improvement in market
opportunities.'

About Biotest
Biotest AG, Dreieich, Germany, is a company that researches and
manufactures pharmaceutical, biotherapeutic and diagnostic products and has
specialised in immunology and haematology. In its Pharmaceutical segment,
Biotest develops immunoglobulins, clotting factors and albumins based on
human blood plasma. These are used for diseases of the immune system or
haematopoietic system. In the Biotherapeutic segment, Biotest researches
into the clinical development of monoclonal antibodies, including in the
indications of rheumatoid arthritis and blood cancer. The Diagnostic
segment spans reagents and serology and microbiology systems which are
used, for example, in blood transfusions. Biotest has around 1,200
employees worldwide and its shares are listed in the Frankfurt Stock
Exchange's Prime Standard.

 
Biotest AG: 
Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de
Dr. Marion Wendorff, Tel: +49 (0) 6103 801-520, e-mail:
marion_wendorff@biotest.de
Fax: +49 (0) 6103 801-347

WKN, ISIN ordinary share: 522720, DE0005227201
WKN, ISIN preference share: 522723, DE0005227235
Listed: Prime Standard/official trading
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart 


About Heipha
heipha Dr. Müller GmbH is an affiliate of Biotest AG, which has a 51%
shareholding in the company. heipha is a leading manufacturer of high
quality culture media for the pharmaceutical, cosmetics and food industry
as well as for microbiological diagnostics in medicine and veterinary
medicine. In addition to the standardised culture media in petri dishes,
heipha also offers contact plates for hygiene monitoring, sedimentation
plates for obtaining bacterial count data from ambient air as well as
special product variants for use in cleanrooms and isolators. All corporate
divisions are certified under quality assurance regualtions. The company's
production site is located in Eppelheim near Heidelberg.

heipha Dr. Müller GmbH:
Harro Walger, Ph.D.
Managing Director 
Lilienthalstraße 16
D-69214 Eppelheim
www.heipha.de





DGAP 15.06.2007 
----------------------------------------------------------------------
 
Language:     English
Issuer:       Biotest AG
              Landsteinerstr. 5
              63303 Dreieich Deutschland
Phone:        +49 - 6103 / 801 - 0
Fax:          +49 - 6103 / 801 - 150
E-mail:       mail@biotest.de
www:          www.biotest.de
ISIN:         DE0005227201, DE0005227235
WKN:          522720, 522723
Indices:      
Listed:       Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in
              Berlin-Bremen, Düsseldorf, Hamburg, Stuttgart
 
End of News                                     DGAP News-Service
 
---------------------------------------------------------------------------